.tb-field[data-toolset-blocks-field="571e4565ae0dc7f4c06a6bfd8334ccbd"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="d4d700e9430e0c6e24db2dbcc7c0e66c"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="c35d9a7279448f10d949ebc7e457ae45"] { text-align: left;justify-content: flex-start; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { background-color: rgba( 217, 217, 217, 0.13 );padding: 10px;margin-bottom: 15px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 215, 213, 213, 1 );grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-field[data-toolset-blocks-field="627e912eb953c8ed786ea0c7e10207ea"] { font-size: 14px;text-align: left;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }   h1.tb-heading[data-toolset-blocks-heading="4273ccf7ca31e5697065fdb41a036bd2"]  { font-size: 26px; }  .wpv-custom-search-filter-submit[data-toolset-views-custom-search-submit="8ca7a9b3f80df5aa18fe74ad2a58d731"] { text-align: left; } @media only screen and (max-width: 781px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } @media only screen and (max-width: 599px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } 

News and Press Releases

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

27 January 2026 -- Illinois, US -- Tempus AI, Inc, a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 27, 2026

Tempus

support@tempus.com

600 W Chicago Ave. Ste 510, Chicago, IL 60654

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

19 January 2026 -- Bengaluru, India -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 19, 2026

Syngene

Biocon Park, SEZ, Bommasandra Industrial Area – Phase-IV, Jigani Link Road, Bangalore, Karnataka – 560 099

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Issued and pending claims expected to protect ALTO-207 into the mid-2040s 14 January 2026 -- California, US -- Alto Neuroscience, Inc, a clinical-stage biopharmaceutical company focused on the development of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2026

Alto Neuroscience

info@altoneuroscience.com

650 Castro Street, Suite 450 Mountain View, CA 94041

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement

Initiative Focused on Scaling Advanced Cell and Gene Therapy to Enhance Patient Access 14 January 2026 -- Illinois, US -- Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced...

Category: BioManufacturing, Biotechnology, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: January 14, 2026

Fresenius Kabi

communications.USA@fresenius-kabi.com

Three Corporate Drive Lake Zurich, Illinois 60047

Integrated DNA Technologies Expands Synthetic Biology Portfolio with Ansa Biotechnologies’ Clonal DNA and XL Clonal DNA Products

New collaboration empowers customers with sequence-perfect constructs as long as 50 kb 14 January 2026 -- California, US -- Integrated DNA Technologies (IDT), a Danaher company and a global leader...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2026

Integrated DNA Technologies (IDT)

custcare@idtdna.com

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

New AI-derived model integrates longitudinal ctDNA and clinical data with digital pathology and tumor sequencing data, to refine recurrence risk assessment and outcomes prediction 13 January 2026 -- Texas, US...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 13, 2026

Natera

13011 McCallen Pass Building A Suite 100 Austin, TX 78753

Automata and CellVoyant Announce Strategic Partnership to Deliver AI-Powered Closed-Loop Cell Culture Workflows

13 January 2026 -- California, US -- Automata, a leading provider of modular, fully-integrated and AI-ready lab automation, and CellVoyant, a pioneer in AI foundation models for ‘live’ label-free cell...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 13, 2026

CellVoyant

info@cellvoyant.com

Origin Workspace 40 Berkeley Square, Bristol BS8 1HP

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker

New NeXT Personal extension empowers clinicians to identify emerging resistance and therapeutically targetable mutations during disease monitoring and surveillance 12 January 2026 -- California, US -- Personalis, Inc, a leader...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026

Personalis

info@personalis.com

6600 Dumbarton Circle Fremont, CA 94555 USA

ConcertAI and Foundation Medicine Integrate Genomic and Clinical Data to Transform Translational Research and Efficient Drug Development

ConcertAI now offers industry’s most comprehensive clinically-linked dataset to life science organizations Dataset encompasses ConcertAI’s full network of industry partners, representing nearly half a million patients Applications span entire drug...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026

Foundation Medicine

Biopharma.leads@foundationmedicine.com

400 Summer Street, Boston, MA 02210

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

FDA written feedback supports: a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting Phase...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026

Relmada Therapeutics

info@relmada.com

2222 Ponce de Leon Blvd. Floor 3 Coral Gables, FL 33134

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 8, 2026

Allogene Therapeutics

210 E. Grand Avenue South San Francisco, CA 94080

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic’s Phase II study of neuroprotective...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 18, 2025

Brainomix

investors@brainomix.com

First Floor, Seacourt Tower West Way Oxford OX2 0JJ

T-CURX Announces $20M Series A First Closing Led by BiomedVC to Fund Pipeline of Clinical-Stage CAR-T Programs and Advance Proprietary Non-Viral In Vivo CAR-T Platform

17 December 2025 -- Würzburg, Germany -- T-CURX GmbH (T-CURX) today announces the first closing of a $20M (€ 17.7M) Series A financing with a syndicate of European and Asian investors...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 17, 2025

T-CURX

info@t-curx.com

Innovations- und Gründerzentrum Würzburg Friedrich-Bergius-Ring 15 97076 Würzburg Deutschland/Germany

Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering

Enables in vivo delivery of LEU011 harnessing the VivoCell Platform 15 December 2025 -- London, UK and Illinois, US -- Leucid Bio, a privately-held biotechnology company developing innovative Chimeric Antigen Receptor...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 15, 2025

Leucid Bio

info@leucid.com

3rd Floor, Bermondsey Wing Guy's Hospital London SE1 9RT

Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome

Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome The...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: December 9, 2025